TransMedics Director Sells 4,142 Shares as Wall Street Maintains Buy Ratings: Is the Stock Still a Buy?

A TransMedics executive trimmed his position by $540,300. Director Edward Basile executed an exercise of 4,142 options with immediate sale of all resulting shares in TransMedics Group (TMDX +0.18%) on October 29, 2025, as disclosed in the SEC Form 4 filing.Transaction summaryMetricValueShares sold4,142Transaction value~$540,300Post-transaction shares2,866Post-transaction value (direct ownership)~$385,000Transaction value is based on the SEC Form 4 weighted average purchase price of $130.45 as of October 29, ...